Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set
the standard for visual outcomes in treating wet macular degeneration. However, they need to
be administered frequently by intraocular injections with the attendant risk of
endophthalmitis, lens damage, retinal detachment, and vitreous hemorrhage. The purpose of
this trial is to see if using photodynamic therapy in combination with ranibizumab will
decrease the number of treatments with ranibizumab.